SLC5A2 and heart failure: The 2021 European Society of Cardiology (ESC) guidelines for HFrEF emphasize four key pharmacological therapies, often referred to as the “four pillars” of heart failure treatment: angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter-2 inhibitors (SGLT2is), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) [116].